




## Tobramycin

Revised: February 15, 2021.

CASRN: 32986-56-4



## Drug Levels and Effects

### Summary of Use during Lactation

Tobramycin is poorly excreted into breastmilk. Newborn infants apparently absorb small amounts of other aminoglycosides, but serum levels with typical three times per day dosages are far below those attained when treating newborn infections and systemic effects of tobramycin are unlikely. Older infants would be expected to absorb even less tobramycin. Because there is little variability in the milk tobramycin levels during multiple daily dose regimens, timing breastfeeding with respect to the dose is of little or no benefit in reducing infant exposure. Data are not available with single daily dose regimens. Monitor the infant for possible effects on the gastrointestinal flora, such as diarrhea, candidiasis (e.g., thrush, diaper rash) or rarely, blood in the stool indicating possible antibiotic-associated colitis.

**Disclaimer:** Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

**Attribution Statement:** LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Maternal use of an ear drop or eye drop that contains tobramycin presents little or no risk for the nursing infant. [1] A task force respiratory experts from Europe, Australia and New Zealand found that inhaled tobramycin is compatible with breastfeeding.[2]

## Drug Levels

*Maternal Levels.* After a single 80 mg intramuscular dose of tobramycin in 5 women, milk levels were measured every hour for 6 hours. Only trace levels were detected in 4 of the samples from 1 to 8 hours after the dose. In the fifth woman, milk levels ranged from 0.4 to 0.52 mg/L over 8 hours, with the highest level found at 4 hours after the dose.[3]

In one patient who received 80 mg of tobramycin every 8 hours by intramuscular injection, milk levels were 0.6 mg/L 1 hour after the dose and 0.58 mg/L 8 hours after the dose.[4]

At 2 months postpartum, a woman was receiving intravenous tobramycin 150 mg 3 times daily plus meropenem for cystic fibrosis. Four days after beginning, milk tobramycin levels were undetectable (<0.18 mg/L) before the infusion and in 6 milk samples taken from 1 to 5 hours after the infusion.[5]

*Infant Levels.* Relevant published information was not found as of the revision date.

## Effects in Breastfed Infants

An infant was breastfed (extent not stated) until the 4th month postpartum. At 2 months of age, his mother was given a 2-week course of tobramycin 150 mg three times daily plus meropenem for a cystic fibrosis exacerbation. infant displayed no change in stool pattern during the maternal treatment and had normal renal function at 6 months of age.[5,6]

## Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

## References

1. Niebyl JR. Use of antibiotic of ear, nose, and throat disorders in pregnancy and lactation. *Am J Otolaryngol.* 1992;13:187–92. PubMed PMID: 1503194.
2. Middleton PG, Gade EJ, Aguilera C, et al. ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases. *Eur Respir J.* 2020;55:1901208. PubMed PMID: 31699837.
3. Takase Z, Shirafuji H, Uchida M, et al. Laboratory and clinical studies on tobramycin in the field of obstetrics and gynecology. *Chemotherapy (Tokyo).* 1975;23:1402–7.
4. Uwaydah M, Bibi S, Salman S. Therapeutic efficacy of tobramycin--a clinical and laboratory evaluation. *J Antimicrob Chemother.* 1975;1:429–37. PubMed PMID: 1107297.
5. Festini F, Ciuti R, Taccetti G, et al. Breast-feeding in a woman with cystic fibrosis undergoing antibiotic intravenous treatment. *J Matern Fetal Neonatal Med.* 2006;19:375–6. PubMed PMID: 16801316.
6. Festini F, Ciuti R, Repetto T, et al. Safety of breast-feeding during an IV tobramycin course for infants of CF women. *Pediatr Pulmonol Suppl* 2004;38:288-9. Abstract. doi:10.1002/ppul.20143

## Substance Identification

### Substance Name

Tobramycin

## **CAS Registry Number**

32986-56-4

## **Drug Class**

Breast Feeding

Lactation

Anti-Infective Agents

Antibacterial Agents

Aminoglycosides